Reversible heart failure: Toxins, tachycardiomyopathy and mitochondrial abnormalities

Postgraduate Medical Journal

Volumn 88, Issue 1046, 2012, Pages 706-712

  Morris, Paul D ^a   Robinson, Tim ^b   Channer, Kevin S ^c  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA GLUTAMYLTRANSFERASE;

ABDOMINAL SWELLING; ABSTINENCE; ADULT; BLOOD PRESSURE; CARDIOMEGALY; CASE REPORT; CENTRAL VENOUS PRESSURE; CONGESTIVE HEART FAILURE; COUGHING; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRINKING BEHAVIOR; DYSPNEA; ECHOCARDIOGRAPHY; ERYTHROCYTE VOLUME; EXERCISE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG CONGESTION; MALE; REVIEW; SMOKING; TACHYCARDIA; THORAX RADIOGRAPHY; WEIGHT GAIN;

ADULT; CALCIUM; CARDIOMYOPATHIES; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MITOCHONDRIA; MYOCARDIAL CONTRACTION; PHARMACEUTICAL PREPARATIONS; TACHYCARDIA; YOUNG ADULT;

EID: 84870529034     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2011-130698     Document Type: Review

References (59)

1. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402.
2. Robinson T, Smith A, Channer KS. Reversible heart failure: the role of inflammatory activation. Postgrad Med J 2011;87:110-15.
3. Kokolis S, Marmur JD, Clark LT, et al. Effects of alcoholism on coronary artery disease and left ventricular dysfunction in male veterans. J Invasive Cardiol 2006;18:304-7.
4. Dancy M, Bland JM, Leech G, et al. Preclinical left ventricular abnormalities in alcoholics are independent of nutritional status, cirrhosis, and cigarette smoking. Lancet 1985;1:1122-5.
5. Bing RJ. Cardiac metabolism: its contributions to alcoholic heart disease and myocardial failure. Circulation 1978;58:965-70.
6. Arriola L, Martinez-Camblor P, Larrañaga N, et al. Alcohol intake and the risk of coronary heart disease in the Spanish EPIC cohort study. Heart 2010;96:124-30.
7. Fernández-Sola J, Nicolás JM, Oriola J, et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med 2002;137:321-6.
8. Institute for the Study of Drug Dependence. UK National Report for the European Monitoring Centre for Drugs and Drug addiction, London: Institute for the Study of Drug Dependence, 1997.
9. Afonso L, Mohammad T, Thatai D. Crack whips the heart: a review of the cardiovascular toxicity of cocaine. Am J Cardiol 2007;100:1040-3.
10. Mouhaffet A, Madu E, Satmary W, et al. Cardiovascular complications of cocaine. Chest 1995;107:1426-34.
11. Bertolet BD, Freund G, Martin CA, et al. Unrecognized left ventricular dysfunction in an apparently healthy cocaine abuse population. Clin Cardiol 1990;13:323-8.
12. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001;345:351-8.
13. Chiueh C, Kopin J. Centrally mediated release of cocaine by endogenous epinephrine and norepinephrine from the sympathoadrenal medullary system of unanesthetised rats. J Pharmacol Exp Ther 1978;205:148-54.
14. Burke WM, Ravi NV. Urinary excretion of cocaine. Ann Intern Med 1990;112:548-9.
15. Tonga G, Tempesta E. Platelet responsiveness and biosynthesis of thrombaxane and prostacyclin in response to in vitro cocaine treatment. Homeostasis 1985;15:100-7.
16. Tracy CM. Tachycardia-mediated cardiomyopathy. Up-To-Date 2002;10.3. http:// www.uptodate.com (accessed 17 Nov 2002).
17. Kasper EK, Agema WR, Hutchins GM, et al. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994;23:586-90.
18. Moe GW, Naik G, Konig A, et al. Early and persistent activation of myocardial apoptosis, bax and caspases: insights into mechanisms of progression of heart failure. Pathophysiology 2002;8:183-92.
19. Hanna N, Cardin S, Leung TK, et al. Differences in atrial versus ventricular remodeling in dogs with ventricular tachy pacing induced congestive heart failure. Cardiovasc Res 2004;63:236-44.
20. Meinardi MT, Gietema JA, van Veldhuisen DJ, et al. Long-term chemotherapy related cardiovascular morbidity. Cancer Treat Rev 2000;26:429-47.
21. Arola OJ, Saraste A, Pulkki K, et al. Acute doxorubicin cardiotoxicity involves cardiomyocite apoptosis. Cancer Res 2000;60:1789-92.
22. Hatch GM, McClarty G. Regulation of cardiolipin biosynthesis in H9c2 cardiac myoblasts by cytidine 50-triphosphate. J Biol Chem 1996;271:25810-16.
23. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-17.
24. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900-2.
25. Rossi F, Fillippelli W, Russo S, et al. Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharm Tox 1994;75:99-107.
26. Vasquez-Vivar J, Martasek P, Hogg N, et al. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochem 1997;36:11293-7.
27. Rajagopalan S, Politi PM, Sinha BK, et al. Adriamycin induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988;48:4766-9.
28. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J Clin Invest 1980;65:128-35.
29. Zhou S, Starkov A, Frober MK, et al. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 2001;61:771-7.
30. Schimmel KJ, Richel DJ, Van Den Brink RB, et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30:181-91.
31. Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008;100:1058-67.
32. Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998;16:3502-8.
33. Fumoleau P, Roché H, Kerbrat P, et al; French Adjuvant Study Group. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 2006;17:85-92.
34. Dorr R. Chemoprotectants for cancer chemotherapy. Semin Oncol 1991;18:48-58.
35. Myers CE, Bonow R, Palmeri S, et al. A randomised controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983;10:53-5.
36. Swain WM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318-32.
37. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-52.
38. Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/ m2. Ann Oncol 2000;11:1029-33.
39. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered n a 3-weekly schedule. J Clin Oncol 2005;23:2162-71.
40. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
41. Chien KR. Focus on research: herceptin and the heartda molecular modifier of cardiac failure. N Engl J Med 2006;354:789-90.
42. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65.
43. Chen T, Xu T, Li Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 2011;37:312-20.
44. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009;100:684-92.
45. Bashore TM, Magorien DJ, Letterio J, et al. Histologic and biochemical correlates of left ventricular chamber in man. J Am Col Cardiol 1987;9:734-42.
46. Stanley WC, Lopaschuk GD, Hall JH, et al. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res 1997;33:243-57.
47. Paolisso G, Gambardella A, Galzerano D, et al. Total body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994;43:174-8.
48. Sabbah HN, Sharov VG, Riddle JM, et al. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1992;24:1333-47.
49. Kelly DP, Strauss AW. Inherited cardiomyopathies. N Engl J Med 1994;330:913-19.
50. Fannin SW, Lesnefsky EJ, Slabe TJ, et al. Aging selectively decreases oxidative capacity in rat heart interfibrillar mitochondria. Arch Biochem Biophys 2000;372:1.
51. Lesnefsky EJ, Tandler B, Ye J, et al. Myocardial ischemia decreases oxidative phosphorylation through cytochrome oxidase in subsarcolemmal mitochondria. Am J Physiol 1997;273:1544-54.
52. Hoppel CL, Tandler B, Parland W, et al. Hamster cardiomyopathy: a defect in oxidative phosphorylation in the cardiac interfibrillar mitochondria. J Biol Chem 1982;257:1540-8.
53. Chan K, Truong D, Shangari N, et al. Drug induced mitochondrial toxicity. Expert Opin Drug Metab Toxicol 2005;1:655-69.
54. Wei YH, Lu CY, Lee HC, et al. Oxidative damage and mutation to mitochondrial DNA and age dependent decline of mitochondrial respiratory function. Ann N Y Acad Sci 1998;854:155-70.
55. Moe GW, Marin-Garcia J, Konig A, et al. In vivo TNF-{alpha} inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol 2004;287:H1813-20.
56. From AH. Should manipulation of myocardial substrate utilization patterns be a component of the congestive heart failure therapeutic paradigm? J Card Fail 1998;4:127-9.
57. Bersin RM, Wolfe C, Kwasman M, et al. Improved hemodynamic-function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994;23:1617-24.
58. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized, double-blind, placebo controlled study. J Am Coll Cardiol 1994;24:1310-20.
59. Sanbe A, Tanonake K, Kobayasi R, et al. Effect of long-term therapy with ACE inhibitors on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol 1995;27:2209-22.